Bevacizumab maintenance vs no maintenance during chemotherapy-free intervals in metastatic colorectal cancer: A randomized phase III trial (PRODIGE 9)
Journal of Clinical Oncology Jan 26, 2018
Aparicio T, et al. - Researchers sought to compare bevacizumab maintenance with no maintenance during chemotherapy-free intervals (CFI) in metastatic colorectal cancer after induction chemotherapy. They found that bevacizumab maintenance monotherapy did not improve tumor control duration, CFI duration, progression-free survival, or overall survival.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty -
Paid Market Research Surveys -
Case discussions, News & Journals' summaries
